Dupixent approved in the US as the first-ever biologic medicine for patients with COPD         Dupixent is indicated for the approximately 300,000 adults in the US with inadequately ...

Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on ...

Sanofi announced today that its Q3 2024 Aide mémoire is available on the "Investors" page of the company's website: ...

EADV: New data reinforce Sanofi’s innovative approach and leadership across immune-mediated skin diseases 24 abstracts for Dupixent, including 4 oral presentations, highlight impact of ...

Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly ...

100% of developing countries work towards the UNFCCC goal of having their NAPs in place by 2025, with all new NAPs including specific health targets reflecting national and sub-national priorities.

Sometimes transformative technology comes from unexpected places. In drug development, that often means the intersection of seemingly unrelated technologies or esoteric areas of science. French ...

Sanofi’s commitment to society is long-term, and a longstanding legacy. Our commitment translates into a set of actions to make a positive impact on the lives of people and communities around the ...

Third quarter 2024 results will be reviewed by management during a live audio webcast with the financial community. The presentation will be followed by a Q&A session. Third quarter 2025 results will ...

As Premium Partner of the Paris 2024 Olympic and Paralympic Games and Official Partner of the Paris 2024 Olympic and Paralympic Torches Relays, we celebrate human achievement across various frontiers.

The phenomenon of smoldering-associated worsening in multiple sclerosis has been widely accepted by the medical community, yet much work is needed to fully integrate it into clinical practice.

Confirming the results of CUPID-A, this second pivotal study in biologic-naïve patients met primary and key secondary endpoints, showing treatment with Dupixent resulted in a nearly 50% reduction in ...